• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Hearne Michael S

    4/2/26 4:19:18 PM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AUPH alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Hearne Michael S

    (Last)(First)(Middle)
    #140, 14315 - 118 AVENUE

    (Street)
    EDMONTONT5L 4S6

    (City)(State)(Zip)

    ALBERTA, CANADA

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/23/2026
    3. Issuer Name and Ticker or Trading Symbol
    Aurinia Pharmaceuticals Inc. [ AUPH ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Financial Officer
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    Remarks:
    No securities are beneficially owned.
    /s/ Michael Hearne04/02/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $AUPH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AUPH

    DatePrice TargetRatingAnalyst
    12/3/2025$16.00Outperform → Market Perform
    Leerink Partners
    11/7/2025$21.00Hold → Buy
    Jefferies
    11/5/2025$15.00Outperform → Sector Perform
    RBC Capital Mkts
    7/30/2025$17.00Buy
    H.C. Wainwright
    11/4/2022Outperform → Perform
    Oppenheimer
    5/5/2022$34.00 → $25.00Overweight
    Cantor Fitzgerald
    3/8/2022$30.00 → $22.00Outperform
    SVB Leerink
    3/1/2022$31.00 → $27.00Outperform
    RBC Capital
    More analyst ratings

    $AUPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Tang Kevin bought $12,455,227 worth of shares (814,606 units at $15.29) (SEC Form 4)

    4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

    6/2/26 9:54:36 PM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Tang Kevin bought $12,688,806 worth of shares (900,000 units at $14.10) (SEC Form 4)

    4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

    3/3/26 5:35:12 PM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Tang Kevin bought $13,590,000 worth of shares (1,300,000 units at $10.45) (SEC Form 4)

    4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

    8/5/25 5:31:03 PM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Tang Kevin bought $12,455,227 worth of shares (814,606 units at $15.29) (SEC Form 4)

    4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

    6/2/26 9:54:36 PM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Robertson Stephen P. was granted 115,541 shares, increasing direct ownership by 23% to 621,402 units (SEC Form 4)

    4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

    5/20/26 5:05:22 PM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Hearne Michael S was granted 116,144 shares (SEC Form 4)

    4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)

    5/20/26 5:04:48 PM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC.

    SAN DIEGO, June 3, 2026 /CNW/ - Tang Capital Management, LLC announces that on June 2, 2026, it acquired 206,005 common shares (the "Common Shares") of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (the "Issuer") at a price of US $15.28 per share (approximately CAD $21.13 per share) for an aggregate purchase price of US $3.1 million (approximately CAD $4.35 million) by way of the public market. Immediately prior to the transaction, Tang Capital Management, LLC held 12,838,101 Common Shares of the Issuer. As a result of the purchase, Tang Capital Management, LLC beneficially owns 13,044,106 Common Shares, representing approximately 10.0% of the issued and outstanding Common Shares of the Issuer

    6/3/26 12:43:00 AM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three months ended March 31, 2026 and provided an update on recent business progress. Financial Results Total Revenue: For the three months ended March 31, 2026, total revenue was $77.7 million, up 24% from $62.5 million in the same period of 2025. Net Product Sales: For the three months ended March 31, 2026, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $73.6 million, up 23% from $60.0 million in the same period of 2025. License, Collaboration and Royalty Revenue: For the three months ended March 31, 2026,

    5/7/26 8:00:00 AM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced today it has entered into a definitive merger agreement (the "Merger Agreement") to acquire Kezar Life Sciences, Inc. (NASDAQ:KZR), a biotechnology company focusing on small-molecule therapeutics to treat unmet needs in autoimmunity and cancer, for $6.955 in cash per share of Kezar common stock, plus one non-transferable contingent value right ("CVR"), which represents the right to receive: (i) potential payments relating to the ongoing clinical development or disposition of zetomipzomib; (ii) certain proce

    3/30/26 8:00:00 AM ET
    $AUPH
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aurinia Pharma downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Aurinia Pharma from Outperform to Market Perform and set a new price target of $16.00

    12/3/25 8:29:14 AM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aurinia Pharma upgraded by Jefferies with a new price target

    Jefferies upgraded Aurinia Pharma from Hold to Buy and set a new price target of $21.00

    11/7/25 8:04:44 AM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aurinia Pharma downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Aurinia Pharma from Outperform to Sector Perform and set a new price target of $15.00

    11/5/25 7:26:10 AM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUPH
    SEC Filings

    View All

    SEC Form 144 filed by Aurinia Pharmaceuticals Inc

    144 - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)

    5/11/26 4:11:24 PM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Aurinia Pharmaceuticals Inc

    144 - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)

    5/11/26 4:10:02 PM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aurinia Pharmaceuticals Inc filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

    8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)

    5/11/26 9:20:50 AM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUPH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LUPKYNIS

    Submission status for AURINIA PHARMACEUTICALS, INC.'s drug LUPKYNIS (ORIG-1) with active ingredient VOCLOSPORIN has changed to 'Approval' on 01/22/2021. Application Category: NDA, Application Number: 213716, Application Classification: Type 1 - New Molecular Entity

    1/25/21 11:31:10 AM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUPH
    Financials

    Live finance-specific insights

    View All

    Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three months ended March 31, 2026 and provided an update on recent business progress. Financial Results Total Revenue: For the three months ended March 31, 2026, total revenue was $77.7 million, up 24% from $62.5 million in the same period of 2025. Net Product Sales: For the three months ended March 31, 2026, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $73.6 million, up 23% from $60.0 million in the same period of 2025. License, Collaboration and Royalty Revenue: For the three months ended March 31, 2026,

    5/7/26 8:00:00 AM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress

    Full Year 2025 LUPKYNIS Sales Grew 25% Announces LUPKYNIS Sales Guidance for 2026 of $305 Million to $315 Million Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three and twelve months ended December 31, 2025 and provided an update on recent business progress. Financial Results Total Revenue: For the three and twelve months ended December 31, 2025, total revenue was $77.1 million and $283.1 million, up 29% and 20%, respectively, compared to $59.9 million and $235.1 million, respectively, for the same periods of 2024. Net Product Sales: For the three and twelve months ended December 31, 2025, net product sales of LUPKYNIS, the first FDA-approv

    2/26/26 6:00:00 AM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it will report financial results for the three and twelve months ended December 31, 2025, and provide an update on recent business progress on February 26, 2026. Aurinia's management team will host a webcast and conference call on February 26, 2026, at 8:30 a.m. ET. The link to the webcast is available here. To join the conference call, please dial 877-407-8029 / +1 201-689-8029. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Com

    2/19/26 6:00:00 AM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUPH
    Leadership Updates

    Live Leadership Updates

    View All

    Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it has appointed Craig Johnson to its Board of Directors (the Board) to support its next phase of growth. Mr. Johnson has more than 30 years of experience serving in senior financial management roles and governing companies in the biotechnology industry. He previously served as a director of Ardea Biosciences, Inc., Adamis Pharmaceuticals Corporation, Decipher Biosciences, Inc., La Jolla Pharmaceutical Company, Odonate Therapeutics, Inc. and Mirati Therapeutics, Inc. He currently serves as a director of Heron Therapeutics, Inc. His biography can be found here. The Company also announced that Dr. Robert

    11/7/24 6:10:00 AM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aurinia Announces 2024 Annual General Meeting Results

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced voting results for its 2024 annual general meeting (the Meeting) of shareholders held on June 14, 2024. Shareholders re-elected five of nine incumbent directors to the Board of Directors (the Board). The four directors, while elected under applicable corporate law, who received less than majority support are Peter Greenleaf, Director, President and CEO; Daniel G. Billen, Ph.D., Director, Chair of the Board, Chair of the Compensation Committee, and Member of the Audit Committee; R. Hector MacKay-Dunn, J.D., K.C., Director, Chair of the Governance & Nomination Committee and Member of the Compensation Committ

    6/14/24 12:16:00 PM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ("Aurinia" or the "Company") today announced that its Board of Directors ("the Board") has appointed Dr. Robert T. Foster to the Board. MKT Capital Ltd. (together with its affiliates, "MKT Capital") submitted Dr. Foster as a candidate and worked collaboratively with Aurinia to name him to the Board. In connection with Dr. Foster's appointment, MKT Capital has entered into a cooperation agreement with Aurinia. A complete copy of the cooperation agreement will be available on our profiles on EDGAR and SEDAR. "We are appreciative of MKT's constructive collaboration efforts. Dr. Foster brings talents which can help strengthen the Board even further

    9/21/23 6:00:00 AM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aurinia Pharmaceuticals Inc

    SC 13G/A - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)

    11/14/24 4:47:34 PM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Aurinia Pharmaceuticals Inc

    SC 13D - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)

    9/12/24 4:10:26 PM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Aurinia Pharmaceuticals Inc (Amendment)

    SC 13D/A - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)

    3/20/24 5:23:55 PM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care